Insmed stock rises on FDA priority review for Arikayce
Investing.com· Investing.com· Sep 21, 2026 · 12:37 PM
This is a summary. Read the complete story at Investing.com below.
Read full article at Investing.comRelated Stories
stocksabout 4 hours ago
Nintendo Switch 2 sales plunge 41% as price hikes and memory crunch bite
Sales of Nintendo's flagship Switch 2 plunged in its fiscal second quarter after the Japanese gaming giant rolled out price hikes amid soaring memory costs.
CNBC Stocks
stocksabout 4 hours ago
IMCD third quarter earnings rise 18% to €140.2 million
Investing.com
stocksabout 4 hours ago
Sony posts 45% Q2 profit rise on movies, games boost
Investing.com